Mumbai, Maharashtra, India and New York, United States
WNS (Holdings) Limited (NYSE: WNS), a leading provider of global Business Process Management (BPM) services, today announced that it has extended its service contract with global pharmaceutical leader GlaxoSmithKline (GSK) until December, 2020.
“We are extremely proud to renew our agreement with GSK. For more than a decade, WNS has been a trusted partner driving evidence-based decisions through high-end research and analytics services. Under the agreement with GSK, WNS has set-up a dedicated state-of-the-art Knowledge Center, driven by a team of over 600 industry experts. WNS leverages its deep Pharma domain knowledge, robust analytics capabilities and proprietary frameworks to deliver actionable business insights to GSK,” said Keshav R. Murugesh, Group CEO, WNS.
With a team of over 2,500 research and analytics professionals globally, WNS provides a wide range of analytics services to our clients across Big Data, marketing, digital, HR, and operations. These solutions leverage WNS’ deep domain expertise, proprietary frameworks and technology-enabled capabilities.
WNS (Holdings) Limited (NYSE: WNS), is a leading global business process management company. WNS offers business value to 200+ global clients by combining operational excellence with deep domain expertise in key industry verticals including Travel, Insurance, Banking and Financial Services, Manufacturing, Retail and Consumer Packaged Goods, Shipping and Logistics, Healthcare and Utilities. WNS delivers an entire spectrum of business process management services such as finance and accounting, customer care, technology solutions, research and analytics and industry specific back office and front office processes. As of December 31, 2015, WNS had 31,340 professionals across 39 delivery centers worldwide including China, Costa Rica, India, Philippines, Poland, Romania, South Africa, Sri Lanka, United Kingdom and the United States. For more information, visit www.wns.com.
Safe Harbor Provision
This document includes information which may constitute forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the accuracy of which are necessarily subject to risks, uncertainties, and assumptions as to future events. Factors that could cause actual results to differ materially from those expressed or implied are discussed in our most recent Form 20-F and other filings with the Securities and Exchange Commission. WNS undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.